Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Capital Expenditures (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Capital Expenditures for 6 consecutive years, with $1000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures changed N/A to $1000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $410000.0, a 79.68% decrease, with the full-year FY2025 number at $410000.0, down 79.68% from a year prior.
  • Capital Expenditures was $1000.0 for Q4 2025 at Relay Therapeutics, up from -$1000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $3.4 million in Q4 2021 to a low of -$1.0 million in Q3 2021.
  • A 5-year average of $1.0 million and a median of $590000.0 in 2023 define the central range for Capital Expenditures.
  • Biggest YoY gain for Capital Expenditures was 5271.88% in 2021; the steepest drop was 341.11% in 2021.
  • Relay Therapeutics' Capital Expenditures stood at $3.4 million in 2021, then crashed by 32.64% to $2.3 million in 2022, then plummeted by 94.91% to $118000.0 in 2023, then soared by 92.37% to $227000.0 in 2024, then plummeted by 99.56% to $1000.0 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Capital Expenditures are $1000.0 (Q4 2025), -$1000.0 (Q3 2025), and $26000.0 (Q2 2025).